THE STORY SO FAR

On December 1, 2016, Delhi High Court quashed a government notification that banned the manufacture and sale of 344 fixed dose combination (FDC) drugs citing risks to patient health; India has been battling the problem of unapproved and irrational FDCs for close to two decades now

But data show that the market share of these drugs has been shrinking for quite some time now; top MNCs are, in fact, withdrawing some of their top-selling FDC drugs from the market

The trend, some fear, may harm patient interest, as FDCs are considered cost-effective